The Battle Over Mifepristone Access in 2026

In commemoration of the 26th anniversary of Food and Drug Administration (FDA) approval of Mifepristone, Families USA is reposting this blog, originally published in March 2026, with updates on the legal cases described below. The battle over Mifepristone is far from over, and the threats to women's health and reproductive freedom remain a looming concern. We hope advocates can use this updated information to educate themselves and to inform their conversations with partners around these issues.

FDA Litigation: Where Things Stand

The legal landscape has shifted since March. The three active federal lawsuits are targeting different pieces of Mifepristone access - from how it's dispensed to whether the medication should be approved at all. Advocates should know where each case stands heading into the fall.

• Missouri v. FDA (Ongoing) - In this case, the state seeks to reinstate stricter dispensing requirements by restoring previously approved FDA restrictions that prohibit Mifepristone from being dispensed through pharmacies or by mail.
  • The case remains active in the Eastern District of Missouri, where the Attorney General of Missouri is joined by the attorneys general of Idaho and Kansas in challenging access to mifepristone; Missouri, Idaho and Kansas have amended their complaint to challenge the FDA's approval of generic Mifepristone, in addition to providing mifepristone by telehealth and mail.
• Louisiana v. FDA (Oral arguments heard September 9, 2026; no ruling yet) - The premise of this case is similar to Missouri v.FDA.
  • An appellate court panel ruled for Louisiana in May 2026, reinstating in-person dispensing requirements and applying the restriction nationwide. The Supreme Court immediately stayed that ruling, so mail and telehealth access remains available nationwide. The Fifth Circuit heard oral arguments in September, focused almost entirely on whether Louisiana has standing to bring the case. Following oral arguments, the outcome and timing of the court's next steps remain uncertain.
• Florida v. FDA (Stayed until December 1, 2026) - In this case, the state challenges the FDA's original approval of Mifepristone and subsequent decisions that expanded access to the medication. The aim is to end access to the medication in every state.
  • A Texas trial court judge paused this case brought by the Florida and Texas attorneys general. The states are seeking to revoke Mifepristone's FDA approval outright. The Trump administration requested the pause while it finishes its safety review. The trial court also denied a motion by the manufacturers of mifepristone to dismiss the case.

This means advocates should remain vigilant about the possibility that the courts could limit access to mifepristone, unless state officials or Congress take action to protect access

Provider Attacks: Another Concerning Avenue

The cases above center on challenges to the FDA's regulation of Mifepristone, including its dispensing requirements, conditions of use, and approval. But over the past year, there have also been ongoing, concerning legal efforts to target individual health care providers and prescribers who provide Mifepristone across state lines. States like Texas have been attempting to sue providers in California, Delaware, and New York. These cases highlight the necessity of "shield laws" that protect providers and prescribers. The Center for Reproductive Rights has a good resource describing the importance of shield laws and information about the status of key cases. The Guttmacher Institute also has a good resource on the scope of shield laws across the states.

Want to know more about how to get involved? Check out our What Can Health Care Advocates Do section below.

Originally published March 10, 2026

Mifepristone, commonly known as Mife, is a safe and effective medication approved by the U.S. Food and Drug Administration (FDA) more than 25 years ago. It has been used by millions of patients in the United States. Its safety and effectiveness are supported by extensive clinical research and decades of real-world data, and reaffirmed by the nation's leading medical authorities, including the American College of Obstetricians and Gynecologists (ACOG) and the American Medical Association (AMA).

Despite this overwhelming scientific consensus, Mifepristone is the focus of coordinated political and legal attacks aimed at restricting access to the medication. These challenges could make it more difficult, or even impossible, for patients to obtain timely care. They also raise broader concerns about political interference in the FDA's longstanding authority to evaluate and approve medications based on science, not political or religious ideology.

FDA Review Under Political Pressure

Given sustained pressure from Republican lawmakers and anti-abortion advocates, some observers have questioned why the FDA has not accelerated its review of Mifepristone.

Understanding the stakes requires recognizing how widely used and broadly supported this medication has become. More than 7.5 million Americans have used Mifepristone, and medication abortion now accounts for more than 60 percent of abortions nationwide. Public opinion surveys consistently show that a majority of Americans support access to medication abortion. Polling indicates that 61% of voters support access to abortion medication, and 59% oppose nationwide restrictions on Mifepristone.

If the FDA were to expedite its safety review, publish its findings, and impose new restrictions - or if one of the ongoing lawsuits were to reach a judgment - the issue could quickly become a central debate during the midterm election cycle. A slower regulatory review process may therefore reflect not only procedural caution but also the political realities surrounding reproductive health policy in an election year.

Administration officials have stated that a review is underway, but that it could take "a year or more to conduct."

While federal regulators and administration officials weigh their options, state lawmakers across the country continue to pursue other avenues to restrict access to medication abortion. Notably, a number of ongoing lawsuits could have sweeping consequences for patients, providers, and the future of medication regulation in the United States.

Targeted Legal Attacks on Mifepristone Access

There are multiple active lawsuits across the country seeking either to restrict access to Mifepristone or to protect continued access to the medication. These cases, have the potential for sweeping nationwide consequences.

Two lawsuits filed by Louisiana and Missouri seek to reinstate stricter dispensing requirements. If successful, these cases could restore earlier FDA restrictions that prohibited Mifepristone from being dispensed through pharmacies or by mail in any state. Patients would instead have to travel to a doctor's office, hospital, or clinic to obtain mifepristone, even though it is safer than drugs like Viagra that patients can obtain through telehealth.

These changes would limit the ability of patients in states where abortion is significantly restricted or banned from obtaining the medication by mail from another state where it remains legal. And it goes one step farther to impose the same restriction on patients in states where abortion remains legal and protected. These barriers could force some patients to delay care or forgo it entirely, with particularly significant consequences for people living in rural communities who may not have easy access to a provider or hospital.

A separate lawsuit filed by Florida and Texas takes an even more aggressive approach. That case challenges the FDA's original approval of mifepristone and subsequent decisions that expanded access to the medication. Unlike the other lawsuits, this case seeks to invalidate the FDA's approval entirely - effectively ending access to Mifepristone nationwide.

Because medication abortion now accounts for the majority of abortion in the United States, a ruling that revokes approval would eliminate access to one of the most commonly used methods of abortion nationwide and could set a precedent allowing courts to overturn long-standing decisions made by experienced FDA scientists and safety experts.

Congressional Pressure on the FDA

Litigation is not the only threat to Mifepristone access. Members of Congress have also increased pressure on the FDA to revisit the medication's approval and regulation.

Republicans in the Senate, led by Senator Bill Cassidy, Chair of the Senate Health, Education, Labor, and Pensions Committee, have openly criticized the ongoing availability of the medication. In October of 2025, Chair Cassidy and several colleagues sent a letter to the FDA Commissioner objecting to the approval of a new generic form of Mifepristone and calling for a renewed safety review.

In January of 2026, Chair Cassidy also held a congressional hearing focused on the alleged safety concerns related to Mifepristone. Notably, Louisiana Attorney General Liz Murrill testified at the hearing as she leads a lawsuit seeking to reinstate in-person dispensing requirements for Mifepristone.

Why This Matters for Health Care

Abortion is essential health care. It allows women and people of reproductive age the freedom to make decisions about their health and their futures - whether ending a pregnancy, managing a miscarriage, or receiving urgent, lifesaving care in an emergency room.

The debate over Mifepristone therefore extends far beyond a single medication. At its core, the conflict raises important questions about the role of scientific expertise in federal regulatory decisions and the extent to which political pressure should influence the approval and availability of medications.

What Can Health Care Advocates Do?

Policy and legal developments are evolving quickly. Health care advocates can play an important role in monitoring these developments and communicating their impact to their networks.

Stay Informed

• Stay connected to the Expanding Medication Abortion Access (EMAA) Project, which regularly creates new resources and updates their messaging guidance.
• Monitor the litigation trackers that are updated by Georgetown University Law Center and the UCLA School of Law.
• Join the Families USA Medicaid Coalition and Big Tent meetings for updates on how federal or judicial changes could impact access. To get connected, please email us at: [email protected].

Speak Out

Your voice matters! Ahead of the midterm elections and any further Congressional or administrative action:

• Speak with your U.S. Senators and Representative to explain how changes to Mifepristone access would affect patients, providers, and your state's health care system.
• Hold your members of Congress accountable through coordinated letter campaigns, social media engagement, and direct outreach to congressional staff.
• Add reproductive health priorities, including access to medication abortion, to your organization's broader health policy agendas.
• Encourage individuals in your network to share their experiences with trusted organizations, like your own organization or Families USA, so that their voices can be amplified through social media, advocacy materials, and outreach to members of Congress, while maintaining their privacy.

Broaden the Frame

This fight extends beyond a single medication. At its core, the debate raises fundamental questions about the role of scientific expertise in the federal regulatory process. When speaking publicly, emphasize the broader implications, including:

• The impact on the FDA's gold standard approval process and what political interference could mean for other medications that we all rely on.
• The downstream effects on our health care systems and the ongoing affordability crisis.
• The tension between sweeping federal or judicial action and the statement made by the Supreme Court Justices through the Dobbs v. Jackson Women's Health Organization decision, which positioned abortion regulation as an individual state-level decision. The outcome of these legal and political challenges could shape not only the future of abortion access in the United States but also the integrity of the nation's science-based drug approval process.